Who Owns Theraflu?

• Parent Company: Haleon plc
• Ownership Type: Wholly owned
• Company Type: Publicly Traded
• Stock Ticker: LSE: HLN

• Founded: 1976
• Founders: Novartis (internal development)

• Founded: 2022
• Headquarters: Weybridge, Surrey, United Kingdom
• Company Type: Publicly Traded
• Stock: LSE: HLN
• Revenue: approximately £10.2 billion (FY2025)
• Employees: Approximately 24,000

Visit Haleon plc website

• Headquarters: Basel, Switzerland
• Manufacturing / Operations: United States, Switzerland, Germany

Theraflu operates under Haleon's comprehensive sustainability framework, which focuses on health inclusivity and environmental responsibility. As a consumer health company solely focused on better everyday health, Haleon believes it is uniquely positioned to address social and environmental barriers that prevent people from managing their health effectively.

Environmental Commitments: Haleon has committed to achieving net zero carbon emissions across its value chain by 2040, aligning with The Climate Pledge and Race to Zero initiatives. The company is building resilience across its value chain by cutting carbon emissions, making packaging more sustainable, and managing natural resources responsibly. These environmental efforts directly impact Theraflu's manufacturing and distribution processes, supporting reduced environmental footprint for the cold and flu relief medication.

Sustainable Packaging Innovation: Haleon is actively working on sustainable packaging solutions for healthcare products, including Theraflu. The company participates in externally verified sustainable choice ranges such as Amazon's 'Climate Pledge Friendly' programme and makes direct sustainability statements about its products. In 2024, Haleon improved its sustainability scoring process to make it more quantitative and introduced weighted sustainability scoring for better tracking and reporting.

Health Inclusivity Focus: Haleon's sustainability strategy is built on two pillars: making everyday health more inclusive and lessening environmental impact. This approach extends to Theraflu through initiatives that empower more people to take greater control of their health and wellbeing. The company uses its reach, capabilities, and partnerships to address barriers to health access and education, particularly important for cold and flu prevention and treatment.

Ethical Standards and Transparency: Haleon maintains robust ethical standards that underpin its sustainability progress. The company provides transparent access to current and historical ESG performance through its ESG Reporting Hub, which includes the Health Inclusivity and Sustainability Report, ESG Databook, and other disclosures. While Haleon is classified in the pharmaceutical sector by ESG investor indices due to revenue mix and regulatory exposure, it operates as a consumer company focused on everyday health.

Responsible Sourcing and Manufacturing: Theraflu benefits from Haleon's commitment to responsible sourcing and manufacturing practices. The company ensures that ingredients are sourced sustainably and that manufacturing processes adhere to high environmental and ethical standards. This includes responsible water management, energy efficiency in production facilities, and ethical labor practices throughout the supply chain.

Theraflu has received recognition primarily through its parent company Haleon's achievements and its position as a leading cold and flu relief medication in consumer health rankings and industry assessments.

Consumer Health Rankings: Theraflu consistently ranks among the top over-the-counter cold and flu medications in independent consumer evaluations. U.S. News & World Report has included Theraflu in its rankings of the best OTC daytime cold and flu medicines and flu medicines, recognizing its effectiveness in providing comprehensive symptom relief for cold and flu sufferers. These rankings evaluate medications based on safety, efficacy, and consumer satisfaction.

Market Leadership Recognition: Theraflu maintains strong brand recognition and market presence in the cold and flu relief category. YouGov BrandIndex data has shown that cold medicines, including Theraflu, experience significant seasonal demand increases, with popular brands seeing approximately 78% more customers during peak flu season compared to the beginning of cold season. This seasonal performance demonstrates Theraflu's strong market position and consumer trust.

Parent Company Excellence: Through Haleon, Theraflu benefits from the company's recognition in ESG and sustainability performance. Haleon's commitment to health inclusivity and environmental responsibility has been acknowledged through various sustainability ratings and indices. The company's transparent ESG reporting and progress toward net zero goals have positioned it as a leader in consumer health sustainability.

Product Innovation Recognition: Theraflu's formulation approach, which combines multiple active ingredients for comprehensive cold and flu symptom relief, represents an innovation in over-the-counter medication delivery. The brand's warming relief syrup format and various product formulations have been recognized for providing effective multi-symptom relief in a convenient delivery system.

Healthcare Professional Endorsement: Theraflu is recommended by pharmacists and healthcare professionals as an effective option for cold and flu symptom management. The brand's inclusion in pharmacist-recommended product lists and healthcare provider formularies demonstrates its credibility and effectiveness in clinical practice.

Consumer Trust and Reliability: Theraflu has built consumer trust through decades of consistent performance and safety. The brand's longevity in the market, since its introduction in 1976, and its continued innovation in cold and flu relief have established it as a reliable choice for consumers seeking effective over-the-counter medication.

Theraflu has experienced one significant product recall related to child-resistant packaging requirements, which was addressed promptly by the manufacturer. The recall did not involve issues with the medication itself but rather with packaging safety features.

2013 Child-Resistant Packaging Recall: In February 2013, Novartis Consumer Health Inc. voluntarily recalled 2.3 million units of Theraflu Warming Relief Syrups for Cough, Colds, and Fevers, along with Triaminic Syrup products. The recall affected 183 different product lots manufactured between May 2010 and December 2011. The issue was that the child-resistant closures on the product packaging could come off too easily, failing to meet child-resistant closure requirements.

Safety Concerns and Regulatory Response: The U.S. Consumer Product Safety Commission (CPSC) had received 12 reports of children unscrewing the locked caps, with four children actually taking the medicine. The products contained acetaminophen and diphenhydramine, which are required by the Poison Packaging Act to be sealed with child-resistant packaging due to potential overdose risks. Excessive acetaminophen can cause liver damage, while too much diphenhydramine can cause sedation and breathing difficulties.

Recall Management and Consumer Response: Novartis offered full refunds for affected products and worked with retailers to remove recalled items from store shelves. The Pittsburgh Poison Control Center director Rita Mrvos warned that many affected products might still be in consumers' homes due to the five to seven year shelf life of the medications, particularly in smaller stores with lower product turnover.

Packaging Industry Impact: The recall highlighted the importance of proper child-resistant packaging in the pharmaceutical industry and led to increased scrutiny of packaging safety standards. The incident demonstrated that child-resistant packaging is designed to slow children down rather than completely prevent access, emphasizing the need for proper medication storage by parents and caregivers.

Current Safety Standards: Following the recall, Theraflu and similar products have undergone enhanced packaging safety testing and compliance verification. Current Theraflu products meet all applicable child-resistant packaging requirements and safety standards. The brand, now under Haleon ownership, maintains strict quality control measures for both product formulation and packaging safety.

No Medication Quality Issues: It is important to note that the recall was strictly related to packaging functionality and did not involve any problems with the medication itself, which would have been regulated by the FDA. The active ingredients in Theraflu remained safe and effective when used as directed.